- Home
- ACIU vs AEF Comparison
ACIU vs AEF Comparison
Compare ACIU & AEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIU | AEF |
|---|---|---|
| Founded | 2003 | 1989 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 315.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIU | AEF |
|---|---|---|
| Price | $2.81 | $9.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 262.2K | 191.8K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | N/A |
| Revenue This Year | $706.75 | N/A |
| Revenue Next Year | $321.13 | N/A |
| P/E Ratio | ★ N/A | $16.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $5.39 |
| 52 Week High | $4.00 | $9.99 |
Technical Indicators
Market Signals| Indicator | ACIU | AEF |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 51.92 |
| Support Level | $2.80 | $6.10 |
| Resistance Level | $3.13 | $9.28 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 31.00 | 29.75 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.